DisclosureWe earn commission on partner links; ranking is set by our evidence-based methodology — not advertisers. Read policy
Reviewed by the HealthVetted Editorial
Obesity is a chronic, relapsing medical condition in which excess body fat accumulates to a degree that can harm health. It is recognized as a disease in its own right — not a failure of willpower — and is driven by a complex mix of biology, environment, and behavior, which is also why it usually responds best to long-term medical treatment rather than short-term dieting.
Obesity is defined by the presence of excess body fat (adiposity) sufficient to raise the risk of, or directly cause, health problems. In adults it is most commonly screened for using body mass index (BMI) — weight in kilograms divided by height in meters squared. By the standard cutoffs, a BMI of 30.0 kg/m² or higher is classified as obesity, and a BMI of 40.0 kg/m² or higher is classified as severe (sometimes called "class III") obesity (CDC).
BMI is a screening tool, not a perfect measure of fat. It does not distinguish muscle from fat, and it can misclassify very muscular people or, conversely, miss harmful fat in people of "normal" weight. For this reason, modern frameworks increasingly pair BMI with direct measures of body shape and fat distribution. In January 2025, a global Lancet Diabetes & Endocrinology Commission proposed distinguishing "clinical obesity" — excess adiposity that is already causing organ dysfunction or limiting daily activities — from "preclinical obesity," where excess fat is present and raises future risk but has not yet produced illness. The Commission recommended confirming excess fat with at least one additional measure such as waist circumference, waist-to-hip ratio, or waist-to-height ratio, rather than relying on BMI alone (Lancet, 2025).
Obesity is one of the most common chronic conditions in the United States. CDC surveillance data show that every U.S. state and territory has an adult obesity prevalence of at least 25%, and that prevalence reaches 40% or higher in some states (CDC). In coding terms, obesity is captured under ICD-10 code E66, with subcodes such as E66.01 (morbid/severe obesity due to excess calories) and E66.9 (obesity, unspecified).
It is important to frame obesity accurately: major medical bodies, including the American Medical Association, classify it as a disease influenced by hormones, genetics, the brain's appetite-regulation systems, and the food and activity environment — not simply as a lifestyle choice.
At the simplest level, obesity develops when energy intake chronically exceeds energy expenditure, and the surplus is stored as fat. But that "calories in, calories out" description hides a great deal of biology. The body defends a fairly high "set point" of fat mass through powerful hormonal and brain signals (including leptin, ghrelin, insulin, and GLP-1), which is part of why weight that is lost is so often regained (NIH; StatPearls).
Contributing factors and risk groups include:
Where fat is stored matters as much as how much there is. Visceral fat packed around the abdominal organs is more metabolically harmful than fat under the skin, which is why waist circumference is a useful complement to BMI. Risk also varies by ancestry: some populations, including many of South Asian descent, carry higher metabolic risk at lower BMIs.
Obesity itself is identified by body measurements rather than by a single symptom, and many people with obesity feel well. When symptoms occur, they often reflect the mechanical load of excess weight or the metabolic strain it places on the body:
The greater concern is what obesity does over time. It is a major driver of type 2 diabetes, high blood pressure, high cholesterol, heart disease and stroke, obstructive sleep apnea, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), osteoarthritis, gallstones, certain cancers, and fertility problems (CDC; NIH).
Diagnosis begins with a clinical assessment, not a number in isolation. A clinician typically:
Some specialist settings use staging systems that grade the *impact* of obesity on health (for example, the Edmonton Obesity Staging System) rather than weight alone, because two people at the same BMI can have very different risk. This is the same logic behind the clinical-versus-preclinical distinction: treatment intensity should track actual health impact, not just the scale.
Obesity is treated as a chronic condition, meaning the goal is sustained management rather than a single "cure." Even modest weight loss of 5–10% of body weight meaningfully improves blood pressure, blood sugar, cholesterol, and sleep apnea (NIH). Care is generally layered.
Comprehensive lifestyle change is the first-line treatment and underpins every other option:
Options here are limited. Orlistat is available over the counter in a lower dose (Alli) and works by blocking absorption of some dietary fat; its main side effects are gastrointestinal. The marketplace of unregulated "fat-burning" and herbal supplements is not supported by strong evidence, and these products are not a substitute for proven care.
The FDA has approved several medications for long-term weight management, generally for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as type 2 diabetes, high blood pressure, dyslipidemia, or obstructive sleep apnea (NIDDK; FDA). Real drug classes and agents include:
The incretin-based therapies (semaglutide and tirzepatide) generally produce the largest average weight loss and are increasingly favored when substantial reduction is needed, while orlistat, liraglutide, phentermine-topiramate, and naltrexone-bupropion may suit more moderate goals (2025 clinical guidance; EASO; WHO, 2025). The WHO's 2025 guideline recommends GLP-1 medicines for adults with obesity as part of a comprehensive program of diet, activity, and clinical support — not as a stand-alone fix. A crucial point: these are long-term treatments. Stopping them commonly leads to substantial weight regain and loss of the associated health benefits (WHO, 2025).
Metabolic and bariatric surgery (such as sleeve gastrectomy and Roux-en-Y gastric bypass) is the most effective and durable treatment for severe obesity and is typically considered at a BMI of 40 or higher, or 35 or higher with serious weight-related disease. It produces large, lasting weight loss and frequently puts type 2 diabetes into remission.
Yes — but it requires treating obesity like the chronic condition it is. Prevention focuses on sustainable habits established early: a diet built around whole foods and limited in sugary drinks and ultra-processed foods, regular physical activity, adequate sleep, and stress management. Because the environment heavily shapes behavior, public-health measures (food labeling, school nutrition, walkable communities) also play a role (CDC).
For someone already living with obesity, long-term management means ongoing follow-up rather than a finite "diet." Weight regain is biologically expected after weight loss, which is why maintenance strategies — continued behavioral support, high physical activity, and, when prescribed, continued medication — are central. Framing weight management as lifelong care, free of blame, improves both outcomes and mental health.
It is reasonable to talk with a clinician any time weight is affecting health or quality of life. Seek medical attention promptly for these red flags:
The outlook for obesity is genuinely encouraging when it is treated as a chronic medical condition. Modest, sustained weight loss reduces the risk of diabetes, improves blood pressure and cholesterol, eases sleep apnea and joint pain, and improves quality of life (NIH). Modern incretin medications and bariatric surgery can produce weight loss large enough to reverse or sharply improve many complications, including putting type 2 diabetes into remission for some people.
The main challenge is durability: the body actively resists weight loss, so regain is common without ongoing support, and obesity is best understood as a relapsing condition rather than a one-time problem. People who stay engaged in long-term care — combining behavior change with medication or surgery where appropriate — tend to do far better than those who cycle through short-term diets. Importantly, treating obesity is not about appearance; it is about lowering the risk of serious disease and improving how well and how long a person lives.
Is obesity really a disease, or just a lifestyle problem? Major medical organizations classify obesity as a chronic disease. It is shaped by genetics, hormones, the brain's appetite systems, medications, and the environment — not simply willpower. Recognizing it as a disease is part of why effective medical treatments now exist.
Is BMI a reliable way to diagnose obesity? BMI is a useful screening tool but an imperfect one. It does not measure body fat directly and can misclassify muscular or older individuals. That is why clinicians increasingly add waist circumference or other body-fat measures and assess actual health impact, as recommended by the 2025 Lancet Commission.
Will I regain the weight if I stop weight-loss medication? Frequently, yes. Anti-obesity medications such as semaglutide and tirzepatide are intended as long-term treatments; studies show that stopping them often leads to substantial weight regain (WHO, 2025). Decisions about continuing, adjusting, or stopping should be made with a clinician.
How much weight do I need to lose to improve my health? Losing as little as 5–10% of body weight can meaningfully improve blood sugar, blood pressure, cholesterol, and sleep apnea (NIH). Health benefits begin well before reaching an "ideal" weight.
Are GLP-1 medications safe? For appropriately selected patients they are generally well tolerated, with nausea and other gastrointestinal effects being the most common side effects. They are not suitable for everyone, and a clinician will review your history, including thyroid and pancreatic risk factors, before prescribing.
The US Food and Drug Administration (FDA) has approved six medications for long-term ("chronic") weight management in adults: orlistat (Xenical, Alli), phentermine-topiramate ER (Qsymia), naltrexone-bupropion (Contrave), liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound). The newer GLP-1 and GIP/GLP-1 receptor agonists are the most effective: in clinical trials, semaglutide produced roughly 13-15% average body-weight loss and tirzepatide about 20% (up to roughly 21-22% at the highest dose) over about 68-72 weeks, alongside diet and exercise. Wegovy is also FDA-approved to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease plus obesity or overweight, and (August 2025) for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis. An oral tablet form of semaglutide (oral Wegovy) was FDA-approved in December 2025. Older agents (orlistat, phentermine-topiramate, naltrexone-bupropion, liraglutide) typically produce about 3-11% weight loss. For severe obesity, bariatric (metabolic) surgery such as sleeve gastrectomy and Roux-en-Y gastric bypass is the most effective long-term treatment for eligible patients. All of these treatments carry risks and benefits and require evaluation, prescription, and monitoring by a qualified clinician. This is general information, not medical advice or a product endorsement.
Obesity can be effectively treated and a person can return to a healthier weight, but it is generally considered a chronic, relapsing disease rather than something that is permanently "cured." Because the body defends a higher weight through hormonal and metabolic changes, weight often returns if treatment stops, which is why doctors approach obesity as a long-term condition like high blood pressure. With sustained lifestyle changes, medication, or surgery, many people achieve significant, lasting improvement. Work with a clinician to build an ongoing plan rather than expecting a one-time fix.
Obesity is most commonly screened using body mass index (BMI), with a BMI of 30 or higher defined as obesity and 25 to 29.9 classified as overweight. It is further divided into Class 1 (BMI 30–34.9), Class 2 (BMI 35–39.9), and Class 3 or severe obesity (BMI 40 or higher). Newer 2025 clinical frameworks pair BMI with measures like waist circumference and signs of organ dysfunction, since BMI alone does not directly measure body fat. A clinician can interpret these numbers alongside your overall health, ethnicity, and other risk factors.
Obesity results from complex interactions between genetics, brain and hormone signaling that regulate appetite, eating behaviors, physical activity, and the surrounding environment, rather than from willpower alone. Contributing factors include diets high in calorie-dense food, limited access to affordable healthy food, sedentary lifestyles, poor sleep, and certain medications such as some antidepressants and steroids. In some cases, underlying conditions like hypothyroidism or polycystic ovary syndrome (PCOS) contribute. A clinician can help identify which factors are most relevant for an individual.
Obesity itself often causes few noticeable symptoms, but it raises the risk of serious health conditions and may produce signs like breathlessness on exertion, joint pain, fatigue, and sleep disturbances. It is strongly linked to type 2 diabetes, high blood pressure, cardiovascular disease, obstructive sleep apnea, certain cancers, fatty liver disease, and osteoarthritis. Higher-than-optimal BMI contributes to millions of deaths worldwide each year from these related diseases. Anyone concerned about weight-related symptoms should be evaluated by a healthcare provider.
Treatment usually starts with lifestyle changes such as adjusting diet, increasing physical activity, improving sleep, and behavioral or mental-health support. When these are not enough, prescription medications, including GLP-1 receptor agonists, can be added and typically produce around 15–20% weight loss while taken. For severe obesity or when other treatments fail, bariatric surgery often achieves larger and more durable weight loss, roughly 25–33% of body weight. The right combination depends on your BMI, health conditions, and goals, so treatment decisions should be made with a clinician.
Weight regain is common because the body responds to weight loss by lowering its metabolic rate and increasing hunger hormones, biologically pushing toward the previous weight. This is why obesity is classified as a chronic disease that often needs ongoing management. With GLP-1 medications, appetite regulation typically returns to baseline and weight often comes back once the medication is stopped, whereas bariatric surgery tends to produce more durable results. A long-term maintenance plan developed with a clinician improves the odds of keeping weight off.
Major medical organizations classify obesity as a chronic disease, not simply a lifestyle choice or a matter of willpower. It involves measurable changes in fat tissue, hormones, metabolism, and brain signaling that affect appetite and energy balance. Recognizing it as a disease supports evidence-based treatment and helps reduce stigma. A healthcare provider can assess whether excess body fat is affecting organ function or overall health.
Consider seeing a doctor if your BMI is 30 or higher, or if your BMI is 25 or higher along with conditions like high blood pressure, high blood sugar, sleep apnea, or joint pain. You should also seek care if weight is rising quickly without an obvious cause, which can occasionally signal an underlying medical issue. A clinician can confirm a diagnosis, screen for related conditions, and recommend appropriate treatment. Early evaluation can help prevent or manage obesity-related complications.
Independent, evidence-based reviews — not paid placements. See our full analysis:
This page is for general information and is not medical advice. Always consult a qualified clinician about diagnosis and treatment. Individual results vary.